{"id":"metopimazine","rwe":[{"pmid":"41155953","year":"2025","title":"Metrological Evaluation of Metopimazine HPLC Assay: ISO-GUM and Monte Carlo Simulation Approaches.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"40367443","year":"2026","title":"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis.","finding":"","journal":"The American journal of gastroenterology","studyType":"Clinical Study"},{"pmid":"39749945","year":"2025","title":"Assessing the prevalence of anticholinergic and sedative medications to avoid in older adults from the French Health Data System.","finding":"","journal":"Journal of the American Geriatrics Society","studyType":"Clinical Study"},{"pmid":"38878283","year":"2024","title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.","finding":"","journal":"Expert opinion on drug metabolism & toxicology","studyType":"Clinical Study"},{"pmid":"35676635","year":"2022","title":"A data-driven pipeline to extract potential adverse drug reactions through prescription, procedures and medical diagnoses analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up.","finding":"","journal":"BMC medical research methodology","studyType":"Clinical Study"}],"tags":[{"label":"metopimazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(2) dopamine receptor","category":"target"},{"label":"DRD2","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"HRH1","category":"gene"},{"label":"A04AD05","category":"atc"},{"label":"Active","category":"status"},{"label":"Antiemetics","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":116.703,"date":"","count":102,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 102 times (LLR=117)"},{"llr":77.928,"date":"","count":25,"signal":"Febrile bone marrow aplasia","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=78)"},{"llr":68.177,"date":"","count":33,"signal":"Drug reaction with eosinophilia and systemic symptoms","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=68)"},{"llr":64.874,"date":"","count":30,"signal":"Cholestasis","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=65)"},{"llr":57.142,"date":"","count":35,"signal":"Coma","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=57)"},{"llr":55.82,"date":"","count":20,"signal":"Poisoning deliberate","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=56)"},{"llr":47.27,"date":"","count":32,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=47)"},{"llr":44.006,"date":"","count":23,"signal":"Pancreatitis acute","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=44)"},{"llr":43.595,"date":"","count":22,"signal":"Hepatocellular injury","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=44)"},{"llr":43.177,"date":"","count":11,"signal":"Analgesic drug level increased","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=43)"},{"llr":40.81,"date":"","count":23,"signal":"Hepatitis","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=41)"},{"llr":38.448,"date":"","count":43,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=38)"},{"llr":37.742,"date":"","count":23,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=38)"},{"llr":35.282,"date":"","count":9,"signal":"Apgar score low","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=35)"}],"commonSideEffects":[{"effect":"Acute kidney injury","drugRate":"LLR 117","severity":"common"},{"effect":"Febrile bone marrow aplasia","drugRate":"LLR 78","severity":"common"},{"effect":"Drug reaction with eosinophilia and systemic symptoms","drugRate":"LLR 68","severity":"common"},{"effect":"Cholestasis","drugRate":"LLR 65","severity":"common"},{"effect":"Coma","drugRate":"LLR 57","severity":"common"},{"effect":"Poisoning deliberate","drugRate":"LLR 56","severity":"common"},{"effect":"Hyperkalaemia","drugRate":"LLR 47","severity":"common"},{"effect":"Pancreatitis acute","drugRate":"LLR 44","severity":"common"},{"effect":"Hepatocellular injury","drugRate":"LLR 44","severity":"common"},{"effect":"Analgesic drug level increased","drugRate":"LLR 43","severity":"common"},{"effect":"Hepatitis","drugRate":"LLR 41","severity":"common"},{"effect":"Thrombocytopenia","drugRate":"LLR 38","severity":"common"},{"effect":"Lactic acidosis","drugRate":"LLR 38","severity":"common"},{"effect":"Apgar score low","drugRate":"LLR 35","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vogalene","offLabel":[],"synonyms":["metopimazine hydrochloride","metopimazine HCl","metopimazine","vogalene"],"timeline":[],"approvals":[],"brandName":"Vogalene","ecosystem":[],"mechanism":{"target":"D(2) dopamine receptor, D(3) dopamine receptor, Histamine H1 receptor","targets":[{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"}],"modality":"Small Molecule","drugClass":"metopimazine","explanation":"Imagine your brain is like a city with many different streets. Dopamine is like a messenger that helps different parts of the city communicate with each other. By blocking the D(2) dopamine receptor, metopimazine can help slow down or speed up the flow of this messenger, depending on the situation.","oneSentence":"Metopimazine works by blocking the D(2) dopamine receptor, which can help regulate various physiological processes.","technicalDetail":"Metopimazine acts as a selective antagonist at the D(2) dopamine receptor, which is a subtype of the dopamine receptor family. This action can influence various physiological processes, including motor control, mood regulation, and reward processing."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1784","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=METOPIMAZINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METOPIMAZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:42:06.842597","biosimilars":[],"competitors":[{"drugName":"scopolamine","drugSlug":"scopolamine","fdaApproval":"1979-12-31","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"chlorobutanol","drugSlug":"chlorobutanol","fdaApproval":"","relationship":"same-class"},{"drugName":"dronabinol","drugSlug":"dronabinol","fdaApproval":"1985-05-31","patentExpiry":"Aug 6, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nabilone","drugSlug":"nabilone","fdaApproval":"1985-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"aprepitant","drugSlug":"aprepitant","fdaApproval":"2003-03-27","patentExpiry":"Sep 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rolapitant","drugSlug":"rolapitant","fdaApproval":"2015-09-01","patentExpiry":"Oct 9, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"metopimazine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"scopolamine","brandName":"scopolamine","genericName":"scopolamine","approvalYear":"1979","relationship":"same-class"},{"drugId":"chlorobutanol","brandName":"chlorobutanol","genericName":"chlorobutanol","approvalYear":"","relationship":"same-class"},{"drugId":"dronabinol","brandName":"dronabinol","genericName":"dronabinol","approvalYear":"1985","relationship":"same-class"},{"drugId":"nabilone","brandName":"nabilone","genericName":"nabilone","approvalYear":"1985","relationship":"same-class"},{"drugId":"aprepitant","brandName":"aprepitant","genericName":"aprepitant","approvalYear":"2003","relationship":"same-class"},{"drugId":"rolapitant","brandName":"rolapitant","genericName":"rolapitant","approvalYear":"2015","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06500429","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist","status":"COMPLETED","sponsor":"Neurogastrx, Inc.","startDate":"2024-06-24","conditions":["Overweight and Obesity","Healthy"],"enrollment":120,"completionDate":"2024-09-13"},{"nctId":"NCT04303195","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis","status":"COMPLETED","sponsor":"Neurogastrx, Inc.","startDate":"2020-08-01","conditions":["Diabetic Gastroparesis","Idiopathic Gastroparesis"],"enrollment":161,"completionDate":"2023-02-25"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005826","UNII":"238S75V9AV","CHEBI":"CHEBI:135726","INN_ID":"2178","RXNORM":"29954","UMLSCUI":"C0066469","ChEMBL_ID":"CHEMBL398615","KEGG_DRUG":"D05010","DRUGBANK_ID":"DB13591","PUBCHEM_CID":"26388","IUPHAR_LIGAND_ID":"11140","MESH_SUPPLEMENTAL_RECORD_UI":"C005260"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.0 hours","clearance":"12.14 mL/min/kg","bioavailability":"20%"},"publicationCount":73,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A04AD05","allCodes":["A04AD05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct 10","pmid":"41155953","title":"Metrological Evaluation of Metopimazine HPLC Assay: ISO-GUM and Monte Carlo Simulation Approaches.","journal":"Pharmaceutics"},{"date":"2026 Feb 1","pmid":"40367443","title":"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis.","journal":"The American journal of gastroenterology"},{"date":"2025 May","pmid":"39749945","title":"Assessing the prevalence of anticholinergic and sedative medications to avoid in older adults from the French Health Data System.","journal":"Journal of the American Geriatrics Society"},{"date":"2024 Jun","pmid":"38878283","title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.","journal":"Expert opinion on drug metabolism & toxicology"},{"date":"2022 Jun 8","pmid":"35676635","title":"A data-driven pipeline to extract potential adverse drug reactions through prescription, procedures and medical diagnoses analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up.","journal":"BMC medical research methodology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vogalene, also known as metopimazine, is a small molecule drug that targets the D(2) dopamine receptor. It is a member of the metopimazine drug class, but its commercial status and approved indications are unknown. The drug has a half-life of 4.0 hours and bioavailability of 20%. As a pharmaceutical professional, it is essential to consider its potential safety implications, including its effects on the dopamine system. Further research is needed to determine its full potential and limitations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}